A method of screening a skin whitening agent uses the stromal cell-derived factor 1 (SDF1) promoter region, the correlation between the expression amount of the skin pigment and the expression of the SDF1 promoter is observed and thus it is expected to be available in systems for pre-screening pigmentation substances and pigment reduction materials, and the drugs screened by the method is used for treatment of skin pigment-related diseases.

Disclosed herein are methods and devices for rapid assessment of whether a microorganism present in a sample is susceptible or resistant to a treatment.

Compositions and methods for regulating EGFR amplification in cancer are disclosed.

Provided herein are methods for detecting cells in a subject that express aberrant proteins. Methods are also provided for eliminating such cells expressing aberrant proteins.

A system and method for alerting a healthcare provider to ineffective prescribed medications is provided. A laboratory system receives test results with genetic markers for a patient, queries a database containing medications known to be ineffective in persons having particular genetic markers to determine whether any medications prescribed by, or likely to be prescribed by, a healthcare provider to the patient are known to be ineffective in persons having the same genetic markers as the patient, and transmits an alert containing such information to a healthcare provider system for the healthcare provider.

The present invention relates to a method for providing information on the diagnosis of Parkinson's disease. The present invention also relates to a composition for preventing, ameliorating or treating Parkinson's disease. The present invention uses at least one miRNA whose expression is specifically down- or up-regulated in a Parkinson's disease model. Therefore, the use of the miRNA is effective in diagnosing and treating Parkinson's disease.

Exemplary methods, compositions, kits and uses thereof for treating neoplasia are provided. For example, a method can be provided for treating neoplasia in a subject, including administering to the subject a VRK2 (vaccinia-related kinase 2) inhibitor, alone or in combination with an inhibitor of Programmed cell death receptor-1 (PD-1). The exemplary methods, compositions and kits may improve cancer immunotherapy.

Molecular signatures that function as very sensitive diagnostic biomarker for myocarditis, heart disease and disorders thereof, are identified.

Compositions and methods for the detection and treatment of ADHD are provided.

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.